Biotricity, Inc. - Condensed Consolidated Statements of Cash Flows - USD ($)		3 Months Ended
		Jun. 30, 2018	Jun. 30, 2017
Cash flow from operating activities:
Net loss		$ (2,420,516)	$ (2,303,313)
Adjustments to reconcile net loss to net cash used in operations
Stock based compensation		355,231	221,078
Issuance of shares for services		627,535	155,486
Issuance of warrants for services, at fair value		96,509	142,989
Accretion expense, including day one derivative loss			879,416
Change in fair value of derivative liabilities	[1]		42,128
Changes in operating assets and liabilities:
Accounts receivable		(4,800)
Harmonized sales tax recoverable		(6,103)	7,328
Deposits and other receivables		(3,993)	(6,982)
Accounts payable and accrued liabilities		146,588	(423,015)
Net Cash used in operating activities		(1,209,549)	(1,284,885)
Cash flows from financing activities:
Issuance of shares, net of cash issuance costs		500,000	1,926,780
Proceeds from exercise of warrants		50,835
Net Cash provided by financing activities		550,835	1,926,780
Effect of foreign currency translation		17,724	126,069
Net (decrease) increase in cash during the period		(658,714)	641,895
Cash, beginning of period		843,643	424,868
Cash, end of period		$ 202,653	$ 1,192,832

[1] See Note 6